JP2022500417A - 咬筋肥大症の治療方法 - Google Patents

咬筋肥大症の治療方法 Download PDF

Info

Publication number
JP2022500417A
JP2022500417A JP2021513947A JP2021513947A JP2022500417A JP 2022500417 A JP2022500417 A JP 2022500417A JP 2021513947 A JP2021513947 A JP 2021513947A JP 2021513947 A JP2021513947 A JP 2021513947A JP 2022500417 A JP2022500417 A JP 2022500417A
Authority
JP
Japan
Prior art keywords
units
masseter
botulinum toxin
dose
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021513947A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500417A5 (https=
Inventor
エリザベス リー
ベータ ボーウェン
クリスティン ソモギ
ジョン ディー ロジャーズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2022500417A publication Critical patent/JP2022500417A/ja
Publication of JP2022500417A5 publication Critical patent/JP2022500417A5/ja
Priority to JP2024154914A priority Critical patent/JP2024177185A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Traffic Control Systems (AREA)
JP2021513947A 2018-09-13 2019-09-12 咬筋肥大症の治療方法 Pending JP2022500417A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024154914A JP2024177185A (ja) 2018-09-13 2024-09-09 咬筋肥大症の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731064P 2018-09-13 2018-09-13
US62/731,064 2018-09-13
PCT/US2019/050910 WO2020056204A1 (en) 2018-09-13 2019-09-12 Methods for treatment of masseter muscle hypertrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024154914A Division JP2024177185A (ja) 2018-09-13 2024-09-09 咬筋肥大症の治療方法

Publications (2)

Publication Number Publication Date
JP2022500417A true JP2022500417A (ja) 2022-01-04
JP2022500417A5 JP2022500417A5 (https=) 2022-09-21

Family

ID=68069888

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021513947A Pending JP2022500417A (ja) 2018-09-13 2019-09-12 咬筋肥大症の治療方法
JP2024154914A Pending JP2024177185A (ja) 2018-09-13 2024-09-09 咬筋肥大症の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024154914A Pending JP2024177185A (ja) 2018-09-13 2024-09-09 咬筋肥大症の治療方法

Country Status (11)

Country Link
US (3) US20200085923A1 (https=)
EP (1) EP3849585A1 (https=)
JP (2) JP2022500417A (https=)
KR (1) KR20210057106A (https=)
CN (1) CN112955166A (https=)
AU (2) AU2019337656A1 (https=)
BR (1) BR112021004776A2 (https=)
CA (1) CA3112227A1 (https=)
MX (1) MX2021002993A (https=)
TW (2) TW202434280A (https=)
WO (1) WO2020056204A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230152107A (ko) * 2021-02-26 2023-11-02 이온 바이오파마, 인크. 두통을 치료하는 데 사용하기 위한 신경독소 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035011A2 (en) * 2002-10-15 2004-04-29 Allergan, Inc. Botulinum toxin dental therapies and procedures
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
WO2006073410A1 (en) * 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
RU2535115C1 (ru) * 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
EP3368071B1 (en) * 2015-10-29 2022-01-26 ReVance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035011A2 (en) * 2002-10-15 2004-04-29 Allergan, Inc. Botulinum toxin dental therapies and procedures
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. DERMATOLOG. TREAT., vol. 24, no. 2, JPN6023028416, 2013, pages 133 - 136, ISSN: 0005511038 *
J. MOV. DISORD., vol. 2, no. 2, JPN6023028414, 2009, pages 95 - 97, ISSN: 0005511036 *
MED. ORAL. PATOL. ORAL. CIR. BUCAL., vol. 15, no. 4, JPN6023028415, 2010, pages 649 - 652, ISSN: 0005511037 *
SURG. COSMET. DERMATOL., vol. 8, no. 1, JPN6025003191, 2016, pages 55 - 60, ISSN: 0005511039 *

Also Published As

Publication number Publication date
WO2020056204A1 (en) 2020-03-19
KR20210057106A (ko) 2021-05-20
EP3849585A1 (en) 2021-07-21
MX2021002993A (es) 2021-08-11
JP2024177185A (ja) 2024-12-19
TW202023606A (zh) 2020-07-01
AU2025226702A1 (en) 2025-09-25
TWI835858B (zh) 2024-03-21
US20200085923A1 (en) 2020-03-19
US20230080740A1 (en) 2023-03-16
BR112021004776A2 (pt) 2021-11-09
TW202434280A (zh) 2024-09-01
AU2019337656A1 (en) 2021-05-06
CN112955166A (zh) 2021-06-11
CA3112227A1 (en) 2020-03-19
US20230083250A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
US20240342256A1 (en) Injection paradigm for administration of botulinum toxins
US20240050540A1 (en) Neurotoxin compositions for use in treating headache
US5183462A (en) Controlled administration of chemodenervating pharmaceuticals
US10729751B2 (en) Injection paradigm for administration of botulinum toxins
US8940308B2 (en) Methods for treating depression
AU2025226702A1 (en) Methods for treatment of masseter muscle hypertrophy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240909

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241018